Press Releases

Press Releases

January 22, 2018
BeiGene Announces Closing of $800 Million Public Offering CAMBRIDGE, Mass. and BEIJING, China, Jan. 22, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology
January 17, 2018
BeiGene Announces Pricing of $750 Million Public Offering CAMBRIDGE, Mass. and BEIJING, China, Jan. 17, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology
January 16, 2018
BeiGene Announces Proposed Public Offering CAMBRIDGE, Mass. and BEIJING, China, Jan. 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the